

Statement of Consolidated Unaudited Financial Results for the Quarter and Half year ended 30th September, 2023

| Sr. No. | Particulars | Quarter Ended | | | Half Year Ended | | Rs. in Lakhs |
|---------|---|---------------|-------------|-------------|-----------------|-------------|--------------|
| | | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | Year Ended |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Revenue from Operations | 5,228 | 3,684 | 3,742 | 6,912 | 5,952 | 12,724 |
| 2 | Other Income | 4,787 | 263 | 5,908 | 5,851 | 5,978 | 6,426 |
| 3 | Total Income | 8,015 | 3,947 | 9,650 | 11,963 | 11,930 | 19,151 |
| 4 | Expenses: | | | | | | |
| | Cost of Materials Consumed | 246 | 134 | 236 | 380 | 452 | 692 |
| | Cost of Construction | 796 | 923 | 1,265 | 1,718 | 1,724 | 3,480 |
| | Changes in Inventories of Finished Goods and WIP | (58) | 247 | (109) | 189 | (112) | (60) |
| | Employee Benefit Expenses | 563 | 627 | 634 | 1,190 | 1,255 | 2,404 |
| | Finance Costs | 13 | 13 | 12 | 37 | 29 | 47 |
| | Depreciation and amortisation expense | 186 | 183 | 167 | 370 | 334 | 672 |
| | Other Expenses | 605 | 665 | 614 | 1,891 | 1,906 | 2,175 |
| | Total Expenses | 2,432 | 2,793 | 2,816 | 5,306 | 4,662 | 9,410 |
| 5 | Profit Before Exceptional Items and Tax (3-4) | 5,603 | 1,155 | 6,833 | 6,758 | 7,268 | 9,741 |
| 6 | Exceptional Items | - | - | - | - | - | 1,061 |
| 7 | Profit Before Tax (5-6) | 5,603 | 1,155 | 6,833 | 6,758 | 7,268 | 8,802 |
| 8 | Tax Expenses | | | | | | |
| | Current Tax | 534 | 113 | 436 | 647 | 471 | 372 |
| | Deferred Tax | 196 | 46 | 273 | 242 | 288 | 247 |
| | Short / (Excess) Provision of earlier years | (297) | - | - | (267) | - | (2) |
| 9 | Net Profit after tax for the Period | 5,171 | 995 | 6,124 | 6,199 | 6,509 | 8,962 |
| 10 | Share of Associate's Profit/(Loss) | 1,887 | 3,442 | 5,429 | 7,339 | 3,168 | 11,903 |
| 11 | Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss) | 9,068 | 4,438 | 11,553 | 13,506 | 9,678 | 19,965 |
| 12 | Other Comprehensive Income | | | | | | |
| | A (i) Items that will not be reclassified to Profit or (Loss) | (3,174) | 4,004 | (1,407) | 890 | (8,808) | (24,613) |
| | (ii) Income tax relating to Items that will not be reclassified to Profit or (Loss) | 367 | (453) | 167 | (99) | 1,008 | 2,811 |
| | B (i) Items that will be reclassified to Profit or (Loss) | 74 | (24) | 147 | 49 | 326 | 391 |
| 13 | Total Comprehensive Income/(Loss) for the Period | 6,334 | 7,965 | 10,443 | 14,299 | 2,204 | (2,346) |
| 14 | Paid up Equity Share Capital (Face Value of Rs 2/- per share) | 5,135.64 | 5,135.64 | 5,135.64 | 5,135.64 | 5,135.64 | 5,135.64 |
| 15 | Other Equity (excluding Revaluation Reserve) | | | | | | 1,69,499 |
| 16 | Earnings per equity share (FY Rs. 2/- per share) Basic & Diluted (In Rs.) | 8.59 | 1.73 | 4.49 | 5.26 | 3.77 | 7.42 |



| Sr. No. | Particulars | Quarter Ended | | | Half Year Ended | | Year Ended |
|---------|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 30.09.2023 (Unaudited) | 30.06.2023 (Unaudited) | 30.09.2022 (Unaudited) | 30.09.2023 (Unaudited) | 30.09.2022 (Unaudited) | 31.03.2023 (Audited) |
| 1 | Segment Revenue | | | | | | |
| | Revenue from Operations | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 785 | 944 | 674 | 1,729 | 1,403 | 2,649 |
| | b. Real Estate Business | 2,442 | 2,740 | 3,068 | 5,183 | 4,548 | 10,075 |
| | Total Income from Operations (Net) | 3,228 | 3,684 | 3,742 | 6,912 | 5,952 | 12,724 |
| 2 | Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment) | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 92 | 45 | 46 | 137 | 174 | 203 |
| | b. Real Estate Business | 849 | 976 | 971 | 1,825 | 1,324 | 3,697 |
| | Total | 940 | 1,022 | 1,017 | 1,962 | 1,498 | 3,900 |
| | Unallocable Income and Expenditure | | | | | | |
| | (i) Interest Expense | (13) | (13) | (12) | (27) | (23) | (47) |
| | (ii) Exceptional Items-ARN | - | - | - | - | - | (1,061) |
| | (iii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset | 4,851 | 124 | 5,781 | 4,775 | 5,731 | 5,730 |
| | (iv) Other Income / (Expense) | 25 | 22 | 48 | 47 | 61 | 157 |
| | Total Profit Before Tax | 5,493 | 1,155 | 6,813 | 6,758 | 7,268 | 8,680 |
| 3 | Segment Assets | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 18,414 | 18,674 | 15,318 | 18,414 | 15,318 | 15,278 |
| | b. Real Estate Business | 33,628 | 30,800 | 28,883 | 33,628 | 28,883 | 32,042 |
| | c. Unallocated | 1,74,931 | 1,79,722 | 2,11,741 | 1,74,931 | 2,11,741 | 1,73,139 |
| | Total | 2,26,972 | 2,29,196 | 2,55,942 | 2,26,972 | 2,55,942 | 2,20,458 |
| 4 | Segment Liabilities | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 2,943 | 2,918 | 2,889 | 2,943 | 2,889 | 2,753 |
| | b. Real Estate Business | 8,252 | 6,527 | 6,418 | 8,252 | 6,418 | 6,419 |
| | c. Unallocated | 3,811 | 3,983 | 5,508 | 3,811 | 5,508 | 3,484 |
| | Total | 15,006 | 13,428 | 14,815 | 15,006 | 14,815 | 12,655 |

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- Exceptional item for the year ended 31st March, 2023 represents provision made by the Company towards balance of the principal amount (total principal amount being Rs. 2,052.13 lakhs) for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability. Further, as communicated by the Company with the stock exchanges vide its letter dated 15th May, 2023, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court of India on 26th May, 2023 and the appeal filed by the Company has been admitted.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Place : Vadodra
Date : 08th November, 2023



[Signature]
Chirag Amin
Chairman

Alembic Limited
Statement of Consolidated Assets and Liabilities

Rs. in Lakhs

| Particulars | As at 30th September, 2023 (Unaudited) | As at 31st March, 2023 (Audited) |
|--|--|--|
| ASSETS | | |
| Non-Current Assets | | |
| (a) Property, Plant and Equipments | 13,117 | 13,189 |
| (b) Capital Work-in-Progress | 54 | 13 |
| (c) Investment Property | 21,297 | 18,942 |
| (d) Goodwill | 5 | 5 |
| (e) Financial Assets | | |
| (i) Investments | 38,525 | 37,432 |
| (ii) Investments accounted using Equity Method | 1,36,225 | 1,33,384 |
| (iii) Others | 287 | 285 |
| (f) Other Non-Current Assets | 3,500 | - |
| | 2,19,010 | 2,03,245 |
| Current Assets | | |
| (a) Inventories | 8,654 | 8,861 |
| (b) Financial Assets | | |
| (i) Investments | 146 | 4,540 |
| (ii) Trade Receivables | 2,152 | 2,345 |
| (iii) Cash and Cash Equivalents | 188 | 98 |
| (iv) Bank Balances other than Cash and Cash Equivalents | 129 | 97 |
| (v) Others | 1,080 | 790 |
| (c) Other Current Assets | 1,434 | 410 |
| (d) Current Tax Assets (Net) | 180 | 78 |
| | 13,962 | 17,214 |
| TOTAL - ASSETS | 2,36,972 | 2,20,458 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity Share Capital | 5,136 | 5,136 |
| (b) Other Equity | 2,06,830 | 2,02,068 |
| | 2,11,966 | 2,07,803 |
| Liability | | |
| Non-Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 416 | - |
| (ii) Other Financial Liabilities | 637 | 670 |
| (b) Provisions | 169 | 121 |
| (c) Deferred Tax Liability (Net) | 3,811 | 3,484 |
| | 5,033 | 4,274 |
| Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 84 | - |
| (ii) Trade Payables | | |
| a) total outstanding dues of Micro and Small Enterprises | 229 | 311 |
| b) total outstanding dues of Others | 2,755 | 1,427 |
| (iii) Other Financial Liabilities | 757 | 626 |
| (b) Other Current Liabilities | 3,988 | 3,879 |
| (c) Provisions | 2,160 | 2,138 |
| | 9,973 | 8,581 |
| TOTAL - EQUITY AND LIABILITIES | 2,36,972 | 2,20,458 |

For Alembic Limited

Place : Vadodra
Date : 08th November, 2023



[Signature]
Chairman

| Particulars | Rs. in Lakhs | |
|---|--|--|
| | For the Half Year Ended on 30th September, 2023 (Unaudited) | For the Half Year Ended on 30th September, 2022 (Unaudited) |
| A. CASH FLOW FROM OPERATING ACTIVITIES: | | |
| Net Profit before tax | 6,758 | 7,288 |
| Add: | | |
| Depreciation | 370 | 334 |
| Interest charged | 27 | 23 |
| (Gain) / Loss on sale of Property, Plant and Equipments | (36) | 5 |
| Sundry balances written back (Net) | - | - |
| Other Non cash items | (187) | (81) |
| Less: | | |
| Interest Income | (39) | (57) |
| Dividend Income | (4,591) | (5,685) |
| Operating Profit before change in working capital | 2,321 | 1,826 |
| Working capital changes: | | |
| Add / (Less): | | |
| (Increase) / Decrease in Inventories | 208 | (72) |
| (Increase) / Decrease in Trade Receivables | 103 | (338) |
| (Increase) / Decrease in Other Asset | (4,524) | 29 |
| (Increase) / Decrease in Financial Asset | (292) | 651 |
| Increase / (Decrease) in Trade Payables | 5,247 | (147) |
| Increase / (Decrease) in Financial Liabilities | 96 | (54) |
| Increase / (Decrease) in Other Liabilities | 309 | 1,608 |
| Increase / (Decrease) in Provisions | 52 | 42 |
| Cash generated from operations | (821) | 3,531 |
| Add / (Less): | | |
| Direct taxes paid (Net of refunds) | (452) | (403) |
| Net cash inflow from operating activities (A) | (1,673) | 3,028 |
| B. CASH FLOW FROM INVESTING ACTIVITIES: | | |
| Add: | | |
| Proceeds from sale of Property, Plant and Equipments | 18 | (4) |
| Proceeds from sale / redemption of investments | 11,363 | 5,858 |
| Interest received | 39 | 57 |
| Dividend received | 4,591 | 5,686 |
| Less: | | |
| Purchase of PPE and Investment Property/Increase in CWIP and Capital Advances | 2,784 | 923 |
| Purchase of Investments | 6,966 | 9,890 |
| Increase in Restricted Bank balances other than Cash & Cash Equivalents | 32 | 60 |
| Net cash inflow from Investing activities (B) | 6,919 | 30,872 |
| C. CASH FLOW FROM FINANCING ACTIVITIES: | | |
| Add: | | |
| Proceeds from long term borrowings | 589 | - |
| Less: | | |
| Dividends paid | 5,617 | 4,561 |
| Interest and other finance costs | 27 | 23 |
| Net cash inflow from Financing activities (C) | 5,944 | 4,584 |
| I. Net (Decrease) / Increase in cash and cash equivalents (A+B+C) | 95 | (21) |
| II. Cash and cash equivalents at the beginning of the period | 89 | 117 |
| III. Cash and cash equivalents at the end of the period (I+II) | 184 | 96 |
| IV. Cash and cash equivalents at the end of the period | | |
| Balance with Bank | 187 | 95 |
| Cash on hand | 1 | 1 |
| Cash and cash equivalents | 188 | 96 |

For Alembic Limited

Place: Vadodra
Date: 08th November, 2023Chiraya Amin
Chairman

Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended 30th September, 2023

| Sr. No. | Particulars | Quarter Ended | | | Half Year Ended | | Rs. in Lakhs |
|---------|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 30.09.2023 (Unaudited) | 30.06.2023 (Unaudited) | 30.09.2022 (Unaudited) | 30.09.2023 (Unaudited) | 30.09.2022 (Unaudited) | 31.03.2023 (Audited) |
| 1 | Revenue from Operations | 3,515 | 3,565 | 3,639 | 6,680 | 5,752 | 12,396 |
| 2 | Other Income | 4,786 | 259 | 5,906 | 5,045 | 5,878 | 6,411 |
| 3 | Total Income | 7,931 | 3,824 | 9,545 | 11,725 | 11,729 | 18,727 |
| 4 | Expenses | | | | | | |
| | Cost of Materials Consumed | 246 | 134 | 236 | 380 | 432 | 692 |
| | Cost of Construction | 796 | 923 | 1,263 | 1,718 | 1,724 | 3,489 |
| | Changes in Inventories of Finished Goods and WIP | (58) | 247 | (109) | 189 | (112) | (60) |
| | Employee Benefit Expenses | 563 | 627 | 634 | 1,190 | 1,255 | 2,484 |
| | Finance Costs | 5 | 5 | 4 | 10 | 8 | 36 |
| | Depreciation and amortisation expense | 177 | 174 | 258 | 351 | 326 | 636 |
| | Other Expenses | 606 | 623 | 569 | 1,229 | 914 | 2,000 |
| | Total Expenses | 2,334 | 2,732 | 2,755 | 5,067 | 4,527 | 9,367 |
| 5 | Profit Before Exceptional Items and Tax (3-4) | 5,596 | 1,092 | 6,790 | 6,658 | 7,193 | 9,560 |
| 6 | Exceptional Items | - | - | - | - | - | 1,061 |
| 7 | Profit Before Tax (5-6) | 5,596 | 1,091 | 6,790 | 6,658 | 7,193 | 8,500 |
| 8 | Tax Expenses | | | | | | |
| | Current Tax | 525 | 96 | 427 | 630 | 451 | 325 |
| | Deferred Tax | 196 | 47 | 273 | 243 | 288 | 248 |
| | Short / (Excess) Provision of earlier years | (297) | - | - | (287) | - | - |
| 9 | Net Profit after tax for the Period | 5,143 | 948 | 6,090 | 6,092 | 6,453 | 7,927 |
| 10 | Other Comprehensive Income | | | | | | |
| | (i) Items that will not be reclassified to Profit or (Loss) | (5,117) | 4,067 | (1,438) | 896 | (8,811) | (24,602) |
| | (ii) Income tax relating to items that will not be reclassified to Profit or (Loss) | 367 | (451) | 568 | (86) | 1,009 | 2,811 |
| 11 | Total Comprehensive Income/(Loss) for the Period | 2,393 | 4,502 | 4,820 | 6,896 | (1,349) | (13,864) |
| 12 | Paid up Equity Share Capital (Face Value of Rs 2/- per share) | 5,135.64 | 5,135.64 | 5,135.64 | 5,135.64 | 5,135.64 | 5,135.64 |
| 13 | Other Equity (excluding Revaluation Reserve) | | | | | | 44,594 |
| 14 | Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (in Rs.) | 2.00 | 0.37 | 2.37 | 2.37 | 2.51 | 3.09 |



Alencis Limited
Segment wise Standalone Revenue and Results

| Sr. No. | Particulars | Quarter Ended | | | Half Year Ended | | |
|---------|---|---------------|-----------------|-----------------|-----------------|-----------------|---------------|
| | | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Segment Revenue | | | | | | |
| | Revenue from Operations | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 785 | 944 | 674 | 1,729 | 1,403 | 2,649 |
| | b. Real Estate Business | 2,530 | 2,623 | 2,964 | 4,951 | 4,348 | 9,667 |
| | Total Income from Operations (Net) | 3,115 | 3,568 | 3,639 | 6,680 | 5,752 | 12,316 |
| 2 | Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment) | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 92 | 45 | 46 | 137 | 174 | 203 |
| | b. Real Estate Business | 804 | 925 | 920 | 1,768 | 1,234 | 3,486 |
| | Total | 895 | 970 | 966 | 1,845 | 1,408 | 3,689 |
| | Unallocable Income and Expenditure | | | | | | |
| | (i) Interest Expense | (5) | (5) | (4) | (18) | (8) | (16) |
| | (ii) Exceptional Items-AP | - | - | - | - | - | (1,061) |
| | (iii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset | 4,651 | 124 | 5,785 | 4,775 | 5,733 | 5,730 |
| | (iv) Other Income / (Expense) | 25 | 22 | 48 | 47 | 63 | 157 |
| | Total Profit Before Tax | 5,546 | 1,091 | 6,790 | 6,858 | 7,195 | 8,590 |
| 3 | Segment Assets | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 18,414 | 18,674 | 15,318 | 18,414 | 15,318 | 15,278 |
| | b. Real Estate Business | 32,819 | 30,069 | 28,060 | 32,819 | 28,060 | 31,134 |
| | c. Unallocated | 47,323 | 51,555 | 65,894 | 47,319 | 65,894 | 48,403 |
| | Total | 98,556 | 1,00,298 | 1,09,272 | 98,552 | 1,09,272 | 94,814 |
| 4 | Segment Liabilities | | | | | | |
| | a. Active Pharmaceutical Ingredients Business | 2,943 | 2,918 | 2,389 | 2,943 | 2,389 | 2,753 |
| | b. Real Estate Business | 7,659 | 5,992 | 5,884 | 7,659 | 5,884 | 5,684 |
| | c. Unallocated | 3,898 | 3,479 | 5,585 | 3,898 | 5,585 | 3,479 |
| | Total | 14,499 | 12,389 | 13,858 | 14,499 | 13,858 | 11,916 |

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- Exceptional item for the year ended 31st March, 2023 represents provision made by the Company towards balance of the principal amount (total principal amount being Rs. 2,052.13 lakhs) for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability. Further, as communicated by the Company with the stock exchanges vide its letter dated 15th May, 2023, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court of India on 26th May, 2023 and the appeal filed by the Company has been admitted.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.



For Alencis Limited

Chirayu Ansin
Chairman

Place : Vadodra
Date : 08th November, 2023

Alembic Limited
Statement of Standalone Assets and Liabilities

Rs. in Lakhs

| Particulars | As at 30th September, 2023 (Unaudited) | As at 31st March, 2023 (Audited) |
|--|--|--|
| ASSETS | | |
| Non-Current Assets | | |
| (a) Property, Plant and Equipments | 13,117 | 13,183 |
| (b) Capital Work-in-Progress | 54 | 13 |
| (c) Investment Property | 20,989 | 18,632 |
| (d) Financial Assets | | |
| (i) Investments | 47,200 | 46,107 |
| (ii) Others | 165 | 164 |
| (e) Other Non-Current Assets | 3,500 | - |
| | 85,025 | 78,099 |
| Current Assets | | |
| (a) Inventories | 8,654 | 8,861 |
| (b) Financial Assets | | |
| (i) Investments | - | 4,160 |
| (ii) Trade Receivables | 2,098 | 2,268 |
| (iii) Cash and Cash Equivalents | 135 | 83 |
| (iv) Bank Balances other than Cash and Cash Equivalents | 129 | 97 |
| (v) Others | 1,080 | 790 |
| (c) Other Current Assets | 1,483 | 406 |
| (d) Current Tax Assets (Net) | 123 | 51 |
| | 13,531 | 16,715 |
| TOTAL - ASSETS | 98,556 | 94,814 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity Share Capital | 5,136 | 5,136 |
| (b) Other Equity | 79,010 | 77,763 |
| | 84,145 | 82,899 |
| Liabilities | | |
| Non-Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 456 | - |
| (ii) Other Financial Liabilities | 177 | 212 |
| (b) Provisions | 189 | 121 |
| (c) Deferred Tax Liability (Net) | 3,808 | 3,479 |
| | 4,569 | 3,812 |
| Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 84 | - |
| (ii) Trade Payables | | |
| a) total outstanding dues of Micro and Small Enterprises | 226 | 305 |
| b) total outstanding dues of Others | 2,697 | 1,415 |
| (iii) Other Financial Liabilities | 722 | 385 |
| (b) Other Current Liabilities | 3,953 | 3,861 |
| (c) Provisions | 2,160 | 2,138 |
| | 9,841 | 8,104 |
| TOTAL - EQUITY AND LIABILITIES | 98,556 | 94,814 |

Place : Vadodra
Date : 08th November, 2023



For Alembic Limited

Chirayu Amin
Chairman

| Particulars | Rs. in Lakhs | |
|--|---|---|
| | For the Half Year Ended on 30th September, 2023 (Unaudited) | For the Half Year Ended on 30th September, 2022 (Unaudited) |
| A CASH FLOW FROM OPERATING ACTIVITIES: | | |
| Net Profit before tax | 6,858 | 7,195 |
| Add: | | |
| Depreciation | 864 | 816 |
| Interest charged | 10 | 8 |
| (Gain) / Loss on sale of Property, Plant and Equipments | (36) | 5 |
| Sundry balances written back (Net) | - | - |
| Other Non cash items | (184) | (58) |
| Less: | | |
| Interest Income | (38) | (60) |
| Dividend Income | (4,582) | (5,688) |
| Operating Profit before change in working capital | 3,189 | 3,718 |
| Working capital changes: | | |
| Add / (Less) : | | |
| (Increase) / Decrease in Inventories | 308 | (72) |
| (Increase) / Decrease in Trade Receivables | 260 | (259) |
| (Increase) / Decrease in Other Asset | (4,407) | 38 |
| (Increase) / Decrease in Financial Asset | (292) | 597 |
| Increase / (Decrease) in Trade Payables | 1,203 | (350) |
| Increase / (Decrease) in Financial Liabilities | 269 | 0 |
| Increase / (Decrease) in Other Liabilities | 92 | 1,589 |
| Increase / (Decrease) in Provisions | 52 | 42 |
| Cash generated from operations | (517) | 3,582 |
| Add / (Less) : | | |
| Direct taxes paid (Net of refunds) | (295) | (456) |
| Net cash inflow from operating activities (A) | (812) | 3,047 |
| B CASH FLOW FROM INVESTING ACTIVITIES: | | |
| Add: | | |
| Proceeds from sale of Property, Plant and Equipments | 38 | (4) |
| Proceeds from sale / redemption of Investments | 11,046 | 5,755 |
| Interest received | 88 | 60 |
| Dividend received | 4,551 | 5,686 |
| Less: | | |
| Purchase of PPE and Investment Property/Increase in CWP and Capital Advances | 2,684 | 921 |
| Purchase of Investments | 6,886 | 9,000 |
| Increase in Restricted Bank Balances other than Cash & Cash Equivalents | 52 | 60 |
| Net cash inflow from investing activities (B) | 6,662 | 3,580 |
| C CASH FLOW FROM FINANCING ACTIVITIES: | | |
| Add: | | |
| Proceeds from long term borrowings | 500 | - |
| Less: | | |
| Dividends paid | 5,857 | 4,563 |
| Interest and other finance costs | 10 | 8 |
| Net cash inflow from financing activities (C) | 5,627 | 4,569 |
| I. Net (Decrease) / Increase in cash and cash equivalents (A+B+C) | (5) | (6) |
| II. Cash and cash equivalents at the beginning of the period | 83 | 92 |
| III. Cash and cash equivalents at the end of the period (I+II) | 135 | 86 |
| IV. Cash and cash equivalents at the end of the period | | |
| Balances with Bank | 134 | 85 |
| Cash on Hand | 1 | 1 |
| Cash and cash equivalents | 135 | 86 |

For Alembic Limited

Place : Vadodara
Date : 09th November, 2023Chirayu Amin
Chairman

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Alembic Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th September, 2023 and year to date from 01st April, 2023 to 30th September, 2023 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. Emphasis of Matter

We draw attention to note no 2 to the Consolidated financial results regarding the status of disputed liability related to pending electricity duty matter. The said note describes the status of provision made by the company towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.




.Our opinion is not modified in respect of above matter.

5. The statement includes results of the following entities:

- i. Alembic City Limited (Subsidiary)
- ii. Alembic Pharmaceuticals Limited (Associate)

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflect total assets of Rs. 5,923.68 lakhs as at 30th September, 2023, total revenue of Rs. 441.97 lakhs and Rs. 890.52 lakhs, total net loss after tax of Rs. 16.18 lakhs and Rs. 14.25 lakhs and total comprehensive loss of Rs. 16.10 lakhs and Rs. 13.98 lakhs for the quarter ended 30th September, 2023 and the period ended on that day respectively and net cash inflow of Rs. 42.70 lakhs for the period from 1st April, 2023 to 30th September, 2023. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 3,897.33 lakhs and Rs. 7,339.17 lakhs and total comprehensive income of Rs. 3,913.59 lakhs and Rs. 7,328.61 lakhs for the quarter ended 30th September, 2023 and the period ended on that day respectively, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036



Himanshu Kishnadwala
Partner
Membership No.037391
Place: Mumbai
Date: 8th November, 2023
UDIN: 23037391BGUMFM3639

Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Alembic Limited** ("the Company") for the quarter ended 30th September, 2023 and year to date from 01st April, 2023 to 30th September, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. **Emphasis of Matter**

We draw attention to note no 2 to the standalone financial results regarding the status of disputed liability related to pending electricity duty matter. The said note describes the status of provision made by the company towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.



Our opinion is not modified in respect of above matter.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036



Himanshu Kishnadwala
Partner
Membership No.037391
Place: Mumbai
Date: 8th November, 2023
UDIN: 23037391BGUMFL4949

